Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis
Standard
Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. / Laukhtina, Ekaterina; Mori, Keiichiro; Mostafaei, Hadi; Merseburger, Axel S; Nyirady, Peter; Moschini, Marco; Quhal, Fahad; Schuettfort, Victor M; Pradere, Benjamin; Motlagh, Reza Sari; Enikeev, Dmitry; Shariat, Shahrokh F; European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group.
in: IMMUNOTHERAPY-UK, Jahrgang 13, Nr. 11, 08.2021, S. 917-929.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis
AU - Laukhtina, Ekaterina
AU - Mori, Keiichiro
AU - Mostafaei, Hadi
AU - Merseburger, Axel S
AU - Nyirady, Peter
AU - Moschini, Marco
AU - Quhal, Fahad
AU - Schuettfort, Victor M
AU - Pradere, Benjamin
AU - Motlagh, Reza Sari
AU - Enikeev, Dmitry
AU - Shariat, Shahrokh F
AU - European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group
PY - 2021/8
Y1 - 2021/8
N2 - Aim: We aimed to compare the mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxicity as well as all AEs of currently used regimens of second-line treatment strategies for advanced or metastatic urothelial carcinoma of the bladder. Methods: The MEDLINE and EMBASE databases were searched for articles according to the PRISMA extension statement for network meta-analysis. Results: Five trials comprising 2205 patients met our eligibility criteria. It is highly likely that immunotherapy, as single regimen, has the lowest rates of motor and sensory neuropathies, constipation, abdominal pain, alopecia, decreased appetite, vomiting and febrile neutropenia. Immunotherapy, in combination regimen, has the lowest rates of anemia and fatigue. Conclusion: Immunotherapy, especially as single regimen, demonstrated the highest favorable tolerability to most AEs.
AB - Aim: We aimed to compare the mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxicity as well as all AEs of currently used regimens of second-line treatment strategies for advanced or metastatic urothelial carcinoma of the bladder. Methods: The MEDLINE and EMBASE databases were searched for articles according to the PRISMA extension statement for network meta-analysis. Results: Five trials comprising 2205 patients met our eligibility criteria. It is highly likely that immunotherapy, as single regimen, has the lowest rates of motor and sensory neuropathies, constipation, abdominal pain, alopecia, decreased appetite, vomiting and febrile neutropenia. Immunotherapy, in combination regimen, has the lowest rates of anemia and fatigue. Conclusion: Immunotherapy, especially as single regimen, demonstrated the highest favorable tolerability to most AEs.
U2 - 10.2217/imt-2020-0305
DO - 10.2217/imt-2020-0305
M3 - SCORING: Journal article
C2 - 34078134
VL - 13
SP - 917
EP - 929
JO - IMMUNOTHERAPY-UK
JF - IMMUNOTHERAPY-UK
SN - 1750-743X
IS - 11
ER -
